Tamarse, Marielle .

HRN: 28-12-15  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/17/2025
CO-AMOXICLAV 625MG (TAB)
12/17/2025
12/24/2025
ORAL
625mg
BID
PROM
Checking Final Appropriateness 

Indication:  Prophylaxis    Type of Infection:  Reproductive Tract    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Intervention



Type of Intervention done:

                    

           


Acceptance: